Abstract: A polyester production process employing an esterification system that uses a distillation column to recover alcohol produced from an esterification zone and then utilizes the recovered alcohol to form a paste, which is recirculated back to the esterification zone with little or no cooling.

Abstract: A method of producing an organosilylamine containing a radiation-polymerizable functional group that is useful as a surface treatment agent is provided. The method includes reacting an organosilylamine containing a haloalkyl group, and at least one salt having a radiation-polymerizable functional group selected from the group consisting of alkali metal salts of organic acids having a radiation-polymerizable functional group and alkaline earth metal salts of organic acids having a radiation-polymerizable functional group, at a temperature within a range from 50 to 150° C. An organosilylamine containing a radiation-polymerizable functional group composed of a specific silazane unit is also provided.

Abstract: A process for preparing an organic hydroperoxide, which process comprises: (a) oxidizing an organic compound to obtain an organic reaction product containing organic hydroperoxide; (b) mixing at least part of the organic reaction product of step (a) with a basic aqueous solution to obtain a mixture of basic aqueous solution and the organic reaction product; (c) separating the mixture of step (b) to obtain a separated organic phase containing organic hydroperoxide, and a separated aqueous phase; (d) mixing at least part of the separated organic phase of step (c) with water to obtain a mixture of an aqueous phase and the organic phase; and (e) separating the mixture of step (d) to obtain a separated organic phase containing organic hydroperoxide, and a separated aqueous phase; in which process the separation to a separated organic phase and a separated aqueous phase in step (e) is carried out with the help of a coalescer containing glass fibers.

Abstract: Ligands for transition metals are disclosed herein, which may be used in various transition-metal-catalyzed carbon-heteroatom and carbon-carbon bond-forming reactions. The disclosed methods provide improvements in many features of the transition-metal-catalyzed reactions, including the range of suitable substrates, number of catalyst turnovers, reaction conditions, and efficiency. For example, improvements have been realized in transition-metal-catalyzed cross-coupling reactions.

Abstract: On producing a purified borazine compound, a borazine compound is filtrated under an atmospheric condition of a water content of not higher than 2000 volume ppm. Or, on filling a borazine compound into a container, the above described borazine compound is filled into the above described container under an atmospheric condition of a water content of not higher than 2000 volume ppm. Or, as a container for preservation for preserving a borazine compound, a container for preserving a borazine compound, which has withstanding pressure of not lower than 0.1 MPa, is used.

Abstract: Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.

Abstract: The invention provides a synthetic and manufacturing process for the preparation of the anticancer drug, fluorapacin, bis(4-fluorobenzyl)trisulfide, and related trisulfide derivatives on large scale. Also provided are processes for the purification and isolation of fluorapacin having high purity and improved stability.

Abstract: The present invention provides a process for preparing dinitrotoluene, comprising the steps of a) reacting toluene with nitric acid in the presence of sulphuric acid to give mononitrotoluene, b) separating the reaction product from step a) into an organic phase comprising mononitrotoluene and an aqueous phase comprising sulfuric acid, c) reacting the organic phase comprising mononitrotoluene with nitric acid in the presence of sulphuric acid to give dinitrotoluene, d) separating the reaction product from step c) into an organic phase comprising dinitrotoluene and an aqueous phase comprising sulfuric acid, wherein the reaction product from step a) has a content of toluene of from 3.0 to 8% by weight, based on the organic phase, and a content of nitric acid of from 0.1 to 1.2% by weight, based on the aqueous phase, and the phase separation in step b) is effected in such a way that further reaction of the toluene with the nitric acid is prevented.

Abstract: There are provided compositions comprising a first compound selected from the group consisting of compounds of formulas (Ib), (III), (V), and (VII), and a second compound selected from the group consisting of compounds of formulas (IIb), (IV), (VI), and (VIII): Various chemical entities can be used for R4 to R11. These compositions can be particularly useful as anti-static agents or as electron activable precursors to a redox couple.

Abstract: Method of producing compounds of the general formula XPR2(OR1)??Ia where X is chlorine, bromine or iodine and R1 is an organic radical, by reacting compounds of the general formula X2PR2??II, in which X has the meaning given above and R2 is an organic radical, with compounds of the general formula R1OH??III, in which R1 has the meaning given above, to give a mixture IV, in that a) the postreaction is carried out at a temperature of from 50 to 240° C. and a pressure of from 0.001 to 0.9 bar, b) from the mixture IV the compounds Ia are separated off from the compounds PR2(OR1)2??Ib and, if appropriate, the compounds II and c) compounds Ib and, if appropriate, unreacted compounds II are returned to the synthesis stage.

Abstract: The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.

Abstract: Novel processes for preparing arylsulfur pentafluorides are disclosed. Processes include reacting at least one aryl sulfur compound with a halogen and a fluoro salt to form an arylsulfur halotetrafluoride. The arylsulfur halotetrafluoride is reacted with a fluoride source to form a target arylsulfur pentafluoride.

Abstract: The invention relates to a process for preparing polyisocyanates by reacting organic amines with phosgene, wherein the reaction is carried out in at least three stages, with the first stage being carried out in a mixing apparatus, the second stage in at least one residence apparatus and the third stage in at least one separation apparatus and the pressure in each successive stage being lower than that in the previous stage.

Abstract: The present invention relates to multimeric oleamide derivatives having connexin 26 inhibitory activities and embraces the dimer oleamide derivatives represented by the following formula (1) or a pharmacologically acceptable salt thereof: where n denotes an integer of 3, 5, or 8. The novel oleamide derivatives of the present invention can be used not only as research reagents, but also in a wide industrial field because they exhibit useful bioactivities such as cancer metastasis/growth inhibition. Thus they have various applications, such as in medicines, supplements, and functional foods, in addition to cancer-preventive and cancer-therapeutic drugs.

Abstract: The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.

Abstract: A method of synthesizing a heteroleptic, multiple metal-containing metallocyclic catalyst, particularly suited for asymmetric catalysis, comprising combining a plurality of plural functional group-containing, monodentate ligands of complementary chirality, said plural functional groups being tethered to each other by tethers in the presence of a scaffold-structural metal Ms or derivative thereof, wherein at least one functional group on each ligand combines to ligate Ms to form a bidentate, Ms centered ligand scaffold containing the remaining functional groups and combining said bidentate ligand scaffold with a catalytic metal Mc or derivative thereof whereby the remaining functional groups combine to ligate Mc, thereby forming said catalyst.

Abstract: Alkyl(methoxymethyl)trimethylsilanylmethylamines are prepared by reacting alkyltrimethylsilanylmethylamines with a substantially equimolar amount of paraformaldehyde and methanol in the presence of a base.

Abstract: Taught are pharmaceutical compositions comprising at least one phospholipid having at least one docosahexaenoyl (DHA) residue, such as a lecithin-DHA-type phospholipid, and methods for treating or preventing respiratory failure of a patient comprising administering these pharmaceutical compositions to a patient in need of such treatment or prevention.

Abstract: To provide novel carnitine derivatives and salts thereof that are resistant to hydrolysis in the presence of aqueous media, and also provide external skin preparations and cosmetics that are excellent in storage stability, product life, skin affinity and percutaneous absorption properties. In particular, to provide novel ?-branched acyl carnitine derivatives and salts thereof, external skin preparations and cosmetics comprising specific ?-branched acyl carnitine derivatives and/or salts thereof.

Abstract: N-organylaminoorganyl- and N,N-diorganylaminoorganyl-triorganylsilanes are prepared continuously with high space/time yield, high product purity, and low halide content, while simultaneously increasing process safety, by introducing haloalkyltriorganylsilane and a 1 to 100 fold motor excess of organylamine into a continuous reactor with a residence time which may be less than 10 minutes, thus minimizing competing side reactions.